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Interpretation — After adjustment for comorbidity as an 
important confounder, we observed similar early mortality 
between the 2 fixation techniques.
The question of whether cemented fixation of total hip arthro-
plasty (THA) increases early postoperative mortality, poten-
tially by inducing bone cement implantation syndrome (BCIS) 
or thromboembolism, is fiercely debated (Olsen et al. 2014). 
The 90-day mortality after THA is reported to be 0.7% in a 
systematic review based on 32 observational studies including 
1,129,330 patients (Berstock et al. 2014). The 3 most frequent 
causes of death within 90 days after THA are myocardial 
infarction, thromboembolism, and pneumonia (Pedersen et 
al. 2011). Since death is a rare complication after THA, only 
large register studies will have the statistical power to address 
the question of whether cemented THA fixation indeed con-
fers an increased risk of early mortality.
Analyses based on Norwegian, Finnish, or Swedish register 
data indicate similar 90-day mortality after cemented compared 
with cementless THA, but only a few studies were designed to 
adequately address comorbidity confounding using different 
methods (Garland et al. 2017, Dale et al. 2019, Ekman et al. 
2019). The Norwegian study on 79,557 patients had access to 
ASA class, based on physicians’ preoperative assessment of 
overall health (Dale et al. 2019), whereas the Finnish study on 
62,221 patients had information on comorbid conditions based 
on a hospital discharge register (Ekman et al. 2019). A Swed-
Background and purpose — Current literature indicates 
no difference in 90-day mortality after cemented compared 
with cementless total hip arthroplasty (THA). However, pre-
vious studies are hampered by potential selection bias and 
suboptimal adjustment for comorbidity confounding. There-
fore, we examined the comorbidity-adjusted mortality up to 
90 days after cemented compared with cementless THA per-
formed due to osteoarthritis.
Patients and methods — Using the Nordic Arthro-
plasty Register Association database, 2005–2013, we 
included 108,572 cemented and 80,034 cementless THA 
due to osteoarthritis. We calculated the Charlson comorbid-
ity index of each patient based on data from national patient 
registers. The Kaplan–Meier method was used to estimate 
unadjusted all-cause mortality. Cox regression was used to 
estimate hazard ratios (HR) with 95% confidence intervals 
(CI) for 14 , 30-, and 90-day mortality comparing cemented 
with cementless THA, adjusting for age, sex, comorbidity, 
nation, and year of surgery.
Results — Cumulative all-cause mortality within 90 
days was 0.41% (CI 0.37–0.46) after cemented and 0.26% 
(CI 0.22–0.30) after cementless THA. The adjusted HR for 
cemented vs. cementless fixation was 0.97 (CI 0.79–1.2), 
and similar risk estimates were obtained for mortality within 
14 (adjusted HR 0.91 [CI 0.64–1.3]) and 30 days (adjusted 
HR 0.94 [CI 0.71–1.3]). We found no clinically relevant 
differences in mortality between cemented and cementless 
THA in analyses stratified by age, sex, Charlson comorbidity 
index, or year of surgery.
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ing countries, with a predominance of cemented fixation in 
Sweden and Norway and a much larger proportion of cement-
less fixation in Denmark and Finland (Mäkelä et al. 2014b). 
Thus, the motivation for performing our study was the possi-
bility to cope with the selection bias by analysing patients from 
all Nordic countries together and to improve the adjustment 
for comorbidity confounding compared with previous studies. 
In addition, we examine whether age, sex, and calendar year 
are effect modifiers in the association between fixation and 
mortality, which was not examined in previous studies. 
We thus designed an international register-based cohort 
study aimed at comparing mortality within 0–14, 0–30, and 
0–90 days after cemented and cementless THA performed due 
to osteoarthritis with adjustment for comorbidities at the time 
of surgery. 
Patients and methods
Study design and sources of data
The study was designed as a population-based cohort study 
on primary THA procedures performed in Denmark, Finland, 
Norway, and Sweden during 2005–2013, and the cohort was 
obtained from the combined NARA database. The database 
includes a common set of variables collected in all partici-
pating countries. Due to personal identification numbers used 
in all Nordic countries it is possible to further link national 
arthroplasty register data to data from national patient regis-
tries in each country, and then to anonymize and transfer data 
to a common NARA database.
Study population
Using the NARA database, we included all primary cemented 
and cementless THAs performed due to osteoarthritis during 
the period 2005 to 2013. Only 1st unilateral THAs were 
included. Some of the exclusion criteria were already applied 
on the national level before transferring data to NARA, whereas 
other exclusion criteria were applied in the NARA dataset. The 
hybrid THA were excluded from the study population. Thus, 
the final study population included 188,606 THA patients 
(Table 1). The index date was defined as the date of THA.
Exposure
The exposure was THA fixation technique, including cemented 
and cementless THA. Hybrid THAs were not included in 
our study since the aim was not to examine the association 
between exposure to hybrids and mortality. 
Outcome
The outcome was time to death within up to 90 days of the 
index date. Information on death was available from the cen-
tral statistics facilities in Denmark (Schmidt et al. 2014), Fin-
land, Norway, and Sweden and was linked to each patient in 
the national registers before transferring the data to NARA 
database. 
Potential confounders
The following variables were included from the NARA data-
base as potential confounders: age (≤ 59, 60–69, 70–79, and 
≥ 80 years), sex, nation (Denmark, Norway, Finland, and 
Sweden), and year of THA (2005–2013).
The level of comorbidity in each individual participant was 
assessed during the 2 years preceding the index date. The 
information on comorbidity was collected from the National 
Discharge Registries of Finland (Sund 2012), Denmark 
(Schmidt et al. 2015), Sweden (Ludvigsson et al. 2011), and 
Norway (Bakken et al. 2020) before transferring to the NARA 
database in anonymized form. We calculated the CCI in the 
adaptation suggested by Quan et al. (2011) (Charlson et al. 
1987) and categorized comorbidities into 4 CCI scores: low 
(score 0: no known comorbidities), mild (score 1), moderate 
(score 2), and severe (score 3 and more). The look-back period 
for CCI calculation was 2 years prior to the index date and 
during the hospitalization for the index THA for the 19 comor-
bidity groups included in CCI and comorbidities that are not 
part of the CCI were not considered. 
Table 1. Flow diagram a
 
  Finland Denmark Norway Sweden
  All OA, first- All OA All OA All OA
  time surgery 2005–2013 2005–2013 2005–2013
No. received from each country 76,066 58,087 49,208 100,383
Keep 2005–2013 51,469   
Keep only cemented/cementless 
   implants (hybrids are excluded) 42,452 48,015 34,721 86,193
Keep non-simultaneous 40,618 47,361 34,639 85,215
Keep first surgery  41,474 30,907 75,608
Remove negative time to death 40,617   
Final study population 40,617 41,474 30,907 75,608
a Some of the exclusion criteria were already applied on the national level before transfer-
ring data to NARA, whereas other exclusion criteria were applied in the NARA dataset.
ish study on 178,784 patients compared 
mortality after cemented and cementless 
THA adjusting for the Charlson comorbid-
ity index (CCI), but the cohort exposed to 
cementless fixation was only about a 10th 
the size of the cohort exposed to cemented 
THA (Garland et al. 2017). That study is 
also hampered by selection bias since the 
practice in Sweden is to select younger and 
fitter patients for cementless fixation. The 
Nordic Arthroplasty Register Association 
(NARA) was established to fuse 4 well-
established Nordic arthroplasty databases 
into a larger framework (Havelin et al. 
2009). The choice of fixation techniques 
varies considerably among the participat-
Acta Orthopaedica 2020; 91 (x): x–x 3
Statistics
We tabulated characteristics of the study population by fixa-
tion technique. Numbers of patients and proportions in each 
category are presented. Means were used to describe age. 
Categorical data were summarized in cross-tables by fixation 
technique.
We used the Kaplan–Meier method to estimate unad-
justed cumulative survival probability by fixation technique. 
We fitted Cox regression models to estimate hazard ratios 
(HR) with 95% confidence intervals (CI). Overall HRs were 
adjusted for age (as continuous variable), sex, CCI score, 
nation, and year of THA surgery, and the inclusion of these 
covariates was based on the assessment of relevance and non-
interference using directed acyclic graphs. Furthermore, we 
studied the association between fixation and mortality stratify-
ing on age, sex, CCI score, and year of index THA surgery. We 
tested for interaction between age and fixation, as well as sex, 
nation and year of surgery and fixation. P-values less than 0.05 
were considered statistically significant.
We used the non-parametric Aalen additive regression 
model as a sensitivity analysis in order to assess graphically 
whether there were time-dependent effects of THA fixation on 
an additive scale, as opposed to the semi-parametric multipli-
cative Cox regression model.  
Follow-up started on the index date and ended on the day 
of death, or December 31, 2013, whichever came first. We 
used SAS version 9.4 (SAS Institute, Cary, NC, USA) to per-
form data management and analyses. The study follows the 
RECORD guidelines (Benchimol et al. 2015). 
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Results
Characteristics of the study population
Among the 188,606 included THA procedures, 58% were 
performed using cemented and 42% using cementless fixa-
tion (Table 2). The proportion of females in the entire study 
population was 58%, mean age at index surgery was 69 years 
(SD 9.7), and the majority of patients (83%) presented with-
out comorbidities classified according to the modified CCI. 
The two fixation cohorts differed with respect to some base-
line characteristics (Table 2). The proportion of females was 
higher in the cohort receiving cemented fixation, the propor-
tion of patients younger than 60 years was considerably higher 
in the cohort operated with cementless fixation, and the pro-
portion of patients with varying degrees of comorbidity was 
slightly higher among those receiving cemented fixation. 
The majority of all cemented procedures were performed 
in Sweden (59%), whereas most cementless procedures were 
registered in Finland and Denmark (36% and 39%). During 
the period 2005–2008, cemented fixation was more frequently 
used than cementless fixation in all 4 countries, whereas in the 
period 2009–2013 we observed the opposite pattern.
Risk of 90-day mortality
During the 1st 90 days of follow-up, the cumulative mortal-
ity after cemented and cementless THA procedures was esti-
mated at 0.41% (CI 0.37–0.46) and 0.26% (CI 0.22–0.30), 
respectively (with 449 deaths after cemented and 208 deaths 
after cementless THA procedures). This was equivalent to an 
unadjusted HR of 1.6 (CI 1.4–1.9) for cemented compared 
with cementless fixation, but after adjustment for age, sex, 
CCI score, nation, and year of index THA, an HR of 0.97 (CI 
0.79–1.2) was attained for cemented compared with cement-
less fixation.
We then analyzed the adjusted risk of 90-day mortality in 
4 separate age groups and found similar 90-day mortality 
between cemented and cementless fixation in the age groups 
60–69, 70–79, and > 80 years of age. However, cemented 
fixation conferred an increased risk of death among patients 
below the age of 59, with an adjusted HR of 3.5 (CI 1.4–8.9; 
Table 3), but the absolute risk difference was 0.09 (CI –0.04 
to 0.21). We tested for interaction between age, sex, nation, 
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and year of surgery and fixation within 90 days and all p-val-
ues were > 0.05.
The risk of revision within 90 days was 0.7% among 
cemented and 1.4% among cementless THA.
Risk of 14- and 30-day mortality
Mortality within 14 days was also analyzed, and during this 
time frame 158 patients (0.14%, CI 0.10–0.19) with cemented 
THA and 72 (0.08%, CI 0.05–0.13) who had received cement-
less THA died, translating into an unadjusted HR of 1.6 (CI 
1.2–2.1) when comparing cemented with cementless THA 
(Table 4). When we fitted a Cox regression model adjusting 
for age, sex, CCI score, nation, and year of index THA, an 
adjusted HR of 0.91 (CI 0.64–1.3) for cemented compared 
with cementless THA was attained (Table 4). 
Mortality within 30 days was 0.21% (CI 0.17–0.26) for 
cemented THA and 0.12% (CI 0.09–0.17) for cementless fixa-
tion. The adjusted HR was 0.94 (CI 0.71–1.3) for cemented 
compared with cementless THA within 30 days of THA.
There was no statistically significant interaction between age 
and fixation, nor between sex, nation, and year of surgery and 
fixation within either 14 or 30 days (all p values were > 0.05).
The Aalen additive risk model confirmed a minor cumu-
lated increased excess risk of death after cemented compared 
with cementless THA in the initial period after THA (up to 10 
days), whereas no difference in the risk was observed after-
wards (Figure). Overall, the Aalen model suggested no effect 
of cementation on the mortality up to 90 days. Since the inten-
sity is low (i.e., a low risk of dying) the curve can be inter-
preted as (almost) the cumulative additional number of dead 
patients for cemented (compared with cementless) over time.
Discussion
Main findings
In this hitherto largest register study on the risk of death after 
THA accounting for comorbidity as an important confounder, 
we find no clinically relevant difference in the absolute or rela-
tive risk of death up to 90 days for cemented compared with 
cementless fixation. 
Cementing is the gold standard for implant fixation in 
elderly patients (Mäkelä et al. 2014a). Even though cemented 
fixation is considered superior in terms of implant survival 
within the 1st decade, the surgeons fear BCIS, with at worst 
cardiac arrest and death of the patient (Donaldson et al. 2009). 
Due to its scarcity, risk factors behind BCIS are difficult to 
investigate; however, anecdotal evidence and a previous inves-
tigation into early mortality after THA including classical and 
reverse hybrids indicates that cementation of the femoral but 
not the acetabular component is the most dangerous moment 
(Garland et al. 2017).
The trend towards using cementless THA may be driven by 
forceful marketing and production-oriented streamlining of 
operative procedures, as well as shorter operating times and 
focus on risk of BCIS (Troelsen et al. 2013, Dale et al. 2019). 
Table 2. Baseline characteristics of patients with cemented and cementless total hip arthroplasty (THA) in the Nordic Arthroplasty Registry 
Association database by country, 2005–2013. Values are count (%)
  All patients Denmark Norway Sweden Finland
Fixation: Cemented Cementless Cemented Cementless Cemented Cementless Cemented Cementless Cemented Cementless
 n = 108,572 n = 80,034 n = 9,954 n = 31,520 n = 22,772 n = 8,135 n = 64,481 n = 11,127 n = 11,365 n = 29,252 
Sex
 Male 39,655 (37) 38,789 (49) 3,446 (35) 15,452 (49) 6,957 (31) 3,091 (38) 25,601 (40) 6,279 (56) 3,651 (32) 13,967 (48)
 Female 68,917 (63) 41,245 (51) 6,508 (65) 16,068 (51) 15,815 (69) 5,044 (62) 38,880 (60) 4,848 (44) 7,714 (68) 15,285 (52)
Age at primary THA
 ≤ 59 5,720 (5.3) 22,525 (28) 215 (2.2) 7,017 (22) 1,132 (5.0) 2,188 (27) 4,186 (6.5) 6,147 (55) 187 (1.6) 7,173 (25)
 60–69 29,760 (27) 33,165 (41) 1,305 (13) 13,981 (44) 5,843 (26) 3,096 (38) 21,050 (33) 4,048 (36) 1,562 (14) 12,040 (41)
 70–79 49,377 (46) 20,033 (25) 5,418 (54) 8,659 (28) 10,326 (45) 2,076 (26) 27,250 (42) 798 (7.2) 6,383 (56) 8,500 (29)
     ≥ 80 23,715 (22) 4,311 (5.4) 3,016 (30) 1,863 (5.9) 5,471 (24) 775 (9.5) 11,995 (19) 134 (1.2) 3,233 (28) 1,539 (5.3)
Charlson comorbidity index
 0, none 89,105 (82) 66,939 (84) 7,119 (72) 25,153 (80) 19,646 (86) 7,028 (86) 53,210 (82) 10,085 (91) 9,130 (80) 24,673 (84)
 1, mild 10,268 (9.5) 6,915 (8.6) 1,370 (14) 3,216 (10) 1,828 (8.0) 698 (8.6) 5,905 (9.2) 621 (5.6) 1,165 (10) 2,380 (8.1)
 2, moderate 6,499 (6.0) 4,388 (5.5) 961 (9.7) 2,182 (6.9) 852 (3.7) 296 (3.6) 3,892 (6.0) 316 (2.8) 794 (7.0) 1,594 (5.4)
 3, severe 2,700 (2.5) 1,792 (2.2) 504 (5.1) 969 (3.1) 446 (2.0) 113 (1.4) 1,474 (2.3) 105 (0.9) 276 (2.4) 605 (2.1)
Year of primary THA
 2005 17,385 (16) 5,446 (6.8) 1,795 (18) 2,186 (6.9) 3,663 (16) 595 (7.3) 9,415 (15) 767 (6.9) 2,512 (22) 1,898 (6.5)
 2006 15,654 (14) 6,278 (7.8) 1,610 (16) 2,456 (7.8) 3,218 (14) 578 (7.1) 8,719 (14) 997 (9.0) 2,107 (19) 2,247 (7.7)
 2007 14,396 (13) 7,145 (8.9) 1,438 (14) 2,901 (9.2) 3,351 (15) 461 (5.7) 8,031 (13) 1,250 (11) 1,576 (14) 2,533 (8.7)
 2008 13,078 (12) 8,080 (10) 1,041 (10) 3,036 (9.6) 3,021 (13) 663 (8.1) 7,631 (12) 1,368 (12) 1,385 (12) 3,013 (10)
 2009 12,537 (12) 9,904 (12) 866 (8.7) 4,401 (14) 2,626 (12) 860 (11) 8,004 (12) 1,502 (14) 1,041 (9.2) 3,141 (11)
 2010 11,587 (11) 10,681 (13) 938 (9.4) 4,074 (13) 2,001 (8.8) 1,169 (14) 7,843 (12) 1,671 (15) 805 (7.1) 3,767 (13)
 2011 10,831 (10) 11,226 (14) 820 (8.2) 4,120 (13) 1,803 (7.9) 1,196 (15) 7,476 (12) 1,777 (16) 732 (6.4) 4,133 (14)
 2012 10,221 (9.4) 11,576 (15) 727 (7.3) 4,134 (13) 1,522 (6.7) 1,303 (16) 7,362 (11) 1,795 (16) 610 (5.4) 4,344 (15)
 2013 2,883 (2.7) 9,698 (12) 719 (7.2) 4,212 (13) 1,567 (6.9) 1,310 (16)    597 (5.3) 4,176 (14)
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The true incidence of death secondary to BCIS is unknown 
in patients undergoing THA due to osteoarthritis, but BCIS 
seems to be more frequent in elderly patients receiving hemi-
arthroplasty due to femoral neck fracture compared with elec-
tive patients with osteoarthritis receiving THA (Olsen et al. 
2014). Previous register studies indicate that the risk of BCIS 
and even delayed thromboembolic events may have been 
overestimated, at least in patients receiving THA for reasons 
other than femoral neck fracture. Comparisons of cemented 
with cementless fixation support the notion that cementation 
is associated with a very small mortality risk increase, if at all, 
both in absolute and in relative terms (Dale et al. 2019, Ekman 
et al. 2019). 
As an exception to this, an analysis based on data from the 
National Joint Registry of England & Wales dataset, led the 
authors to conclude that there is a statistically significant 11% 
increased risk of death associated with cemented compared 
with cementless THA (McMinn et al. 2012), but this interpre-
tation has been contested (Whitehouse et al. 2014). Likewise, 
we showed no difference overall and in the most representa-
tive age groups, namely 60–69, 70–79, and +80 years of age. 
Our observation of an increased relative risk of mortality for 
cemented versus cementless THA only in the youngest age 
group is unexpected, but it is most likely the result of a com-
bination of residual confounding, selection bias, and chance. 
 
Strengths and weaknesses of this study
The important strength of our study is the unique collabora-
tion of 4 national registers used to establish the NARA data-
Table 3. Crude and adjusted hazard ratios (HR) with 95% confi-
dence interval (CI) for 90-day mortality comparing cemented with 
cementless total hip arthroplasties (THA) a 
   
  Number Number Crude Adjusted 
Fixation of deaths at risk HR (95% CI) HR (95% CI) 
Among all
 Cementless 208 80,034 Reference Reference
 Cemented 449 108,572 1.6 (1.4–1.9) 0.97 (0.79–1.2)
Stratified by age     
  ≤ 59 
 Cementless 24 22,525 Reference Reference
 Cemented 11 5,720 1.8 (0.88–3.7) 3.5 (1.4–8.9)
  60–69 
 Cementless 51 33,165 Reference Reference
 Cemented 37 29,760 0.81 (0.53–1.2) 1.6 (0.63–2.1)
  70–79 
 Cementless 78 20,033 Reference Reference
 Cemented 164 49,377 0.85 (0.65–1.1) 1.1 (0.76–1.5)
  ≥ 80 
 Cementless 55 4,311 Reference Reference
 Cemented 237 23,715 0.78 (0.58–1.1) 1.1 (0.77–1.5)
Stratified by gender     
  Male
 Cementless 136 38,789 Reference Reference
 Cemented 212 39,655 1.5 (1.2–1.9) 0.81 (0.61–1.1)
  Female 
 Cementless 72 41,245 Reference Reference
 Cemented 237 68,917 2.0 (1.5–2.6) 1.2 (0.88–1.7)
Stratified by Charlson comorbidity index
  0, no comorbidity 
 Cementless 128 66,939 Reference Reference
 Cemented 270 89,105 1.6 (1.3–2.0) 0.83 (0.63–1.1)
  1, mild comorbidity
 Cementless 41 6,915 Reference Reference
 Cemented 69 10,268 1.1 (0.77–1.7) 1.1 (0.67–1.8)
  2, moderate comorbidity 
   Cementless 16 4,388 Reference Reference
 Cemented 46 6,499 1.9 (1.1–3.4) 1.2 (0.60–2.6)
  3, severe comorbidity
 Cementless 23 1,792 Reference Reference
 Cemented 64 2,700 1.9 (1.2–3.0) 1.3 (0.72–2.3)
Stratified by year of primary operation
  2005–2008 
 Cementless 75 26,949 Reference Reference
 Cemented 255 60,513 1.5 (1.2–2.0) 0.83 (0.61–1.1)
  2009–2013 
 Cementless 133 53,085 Reference Reference
 Cemented 194 48,059 1.6 (1.3–2.0) 1.2 (0.92–1.6)
a We adjusted for age, gender, comorbidity, nation, and year of THA 
surgery in overall analyses. In stratified analyses, we adjusted for 
all variables expect the stratification variable. For each stratification 
category a new Cox model was fitted.
Table 4. Crude and adjusted hazard ratios (HR) with 95% confi-
dence intervals (CI) for 0–14- and 0–30-day mortality comparing 
cemented with cementless total hip arthroplasties
   
  Number Number Crude Adjusted 
Fixation of deaths at risk HR (95% CI) HR (95% CI) 
0–14-day mortality
 Cementless 72 80,034 Reference Reference
 Cemented 158 108,572 1.6 (1.2–2.1) 0.91 (0.64–1.3)
0–30-day mortality     
 Cementless 104 80,034 Reference Reference
 Cemented 234 108,572 1.7 (1.3–2.1) 0.94 (0.71–1.3)
HR adjusted for age, gender, year of surgery, and comorbidity.
Aalen additive plot with cumulative coefficients (y-axis) with 95% con-
fidence interval comparing cemented with cementless total hip arthro-
plasties within 90 days of surgery.
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base, comprising a high number of patients with information 
on comorbidity. This is particularly important when studying 
rare outcomes such as early death after THA surgery. The qual-
ity of the participating national hip registries including both 
completeness and accuracy of data is high (Pedersen and Fern-
stad 2016). Adjustment for comorbidity in studies on mortal-
ity after THA surgery is important, but only a few studies on 
samples of similar size to ours have access to complex health 
administrative datasets containing information on inpatient 
diagnoses prior to surgery, and the use of arthroplasty registry 
data alone to model postoperative mortality has been criticized 
(Whitehouse et al. 2014). Thus, in some studies, the ASA clas-
sification is used as a proxy of comorbidity, but internal vari-
ability within this classification is high. The considerably more 
complex CCI as a measure of comorbidity is a well-established 
tool to adjust for comorbidity in studies aimed at investigating 
short-term mortality after THA (Pedersen et al. 2011, Garland 
et al. 2017). Any misclassification of CCI is most probably 
not related to the mode of THA fixation since the underlying 
healthcare data is prospectively and routinely collected.
Our study has many limitations. Our choice of 90-day mor-
tality as outcome can be questioned although the incidence 
of adverse events within 90 days after surgery is regularly 
reported as a measure of complications by many established 
arthroplasty registers. The longer time has elapsed after major 
surgery the less likely it is that the fixation mode of the index 
THA is related to the event of death (Pedersen et al. 2011). 
THA patients are elderly and can die due to numerous other 
reasons such as comorbid conditions or complications unre-
lated to the THA fixation technique. Thus, some studies inves-
tigating mortality after THA surgery performed due to frac-
ture or osteoarthritis focus on earlier time points, and some 
address each day after surgery by a separate logistic regression 
analysis (Dale et al. 2019, Ekman et al. 2019). We therefore 
additionally explored 14- and 30-day mortality as measures 
of death occurring earlier after index surgery, with findings 
supporting our main conclusions. In order to account for risk 
modifications early during the observation period we also 
undertook Aalen additive risk modelling and found that there 
was a small risk increase associated with cemented fixation 
during the first 14 days after surgery but not thereafter. 
Socioeconomic factors are associated with morbidity, 
mortality, and patient-reported outcome after THA, but 
we had no access to such information. However, a recent 
investigation into the added benefit of including socioeco-
nomic background variables in analyses of early mortality 
after THA indicates that the level of comorbidity may, to a 
certain extent, serve as a proxy measure of socioeconomic 
background (Weiss et al. 2019). In addition, the Scandina-
vian healthcare systems provide public, tax-financed care, 
making socioeconomic factors less pronounced. Further, 
we did not have information on lifestyle factors. It is pos-
sible that younger patients with cementless THA are more 
physically active and fitter, influencing their risk of suffering 
from both intraoperative and early postoperative complica-
tions. The NARA dataset contains no information on causes 
of deaths, which would have enabled us to explore whether 
the youngest age group dies for other reasons than elderly 
patients early after THA surgery. Heterogeneity in data from 
disparate sources and between-country variation can be prob-
lematic, which would affect our study design with data from 
4 Nordic countries, but this seems primarily to be an issue 
when pooled data are used for individual survival-probability 
assessments, an approach not utilized in our study (Bartz-
Johannessen et al. 2019). We also investigated revision rates 
early after index THA and found 0.7% differences to the 
disadvantage of cementless fixation within 90 days, mostly 
due to a pronounced increased risk of periprosthetic fractures 
when compared with cemented fixation. If one used cement-
less fixation in order to avoid cementation-related mortality 
one would have to take the increased risk of early revision 
and the mortality associated with such secondary proce-
dures into account. Finally, we had no information on the 
use of mechanical or chemical thromboprophylaxis, which 
are associated with 90-day mortality after THA (Hunt et al. 
2013, Pedersen et al. 2019). If use of thromboprophylaxis 
is related to fixation method we would be confronted with 
residual confounding in our study. We did not examine the 
association between hybrid THA and mortality. 
Clinical implications
Our study is based on a large population of THA patients from 
4 Nordic countries and examines the association between 
THA fixation and mortality, granting generalizability of the 
study results. We interpret the findings from this and other 
studies as supportive of the continued use of cemented fixation 
of THA performed due to osteoarthritis although an observa-
tional study such as ours cannot entirely establish causal rela-
tionships between mode of fixation and mortality.
Conclusion
After adjustment for comorbidity as an important confounder, 
we observed similar early mortality between the 2 fixation 
techniques, cemented and cementless.
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